Table 1
Crude and adjusted relative risks (RR) obtained from Cox regression analyses predicting failure of new users to persist with statin treatment after two years.
| Crude RR | 95% CI | Adjusted* RR | 95% CI | |
|---|---|---|---|---|
| *Adjusted for all variables listed. | ||||
| †Significantly different from reference category; RR >1 indicates that the variable increases failure to persist on statin treatment; RR <1 indicates that the variable decreases failure to persist on statin treatment. | ||||
| ‡Chronic disease score: 0–1, no or minimal co-morbidity; 2–4, low and average co-morbidity; >4, high co-morbidity. | ||||
| Characteristics at index date | ||||
| Sex | ||||
| Male | 1 | 1 | ||
| Female | 0.98 | 0.93 to 1.04 | 1.01 | 0.95 to 1.07 |
| Age group (year) | ||||
| 0–44 | 1 | 1 | ||
| 45–64 | 0.83 | 0.76 to 0.92 | 0.84† | 0.76 to 0.93 |
| ⩾65 | 0.81 | 0.73 to 0.89 | 0.82† | 0.74 to 0.91 |
| Type of statin | ||||
| Simvastatin | 1 | 1 | ||
| Atorvastatin | 0.90 | 0.84 to 0.97 | 0.90† | 0.83 to 0.96 |
| Fluvastatin | 1.23 | 1.13 to 1.34 | 1.27† | 1.12 to 1.39 |
| Pravastatin | 0.98 | 0.91 to 1.06 | 0.99 | 0.91 to 1.08 |
| Characteristics 1 year before index date | ||||
| Antihypertensive treatment | ||||
| No | 1 | 1 | ||
| Yes | 0.87 | 0.82 to 0.93 | 0.91† | 0.85 to 0.98 |
| Psychotropic agents | ||||
| No | 1 | 1 | ||
| Yes | 1.11 | 1.04 to 1.18 | 1.13† | 1.06 to 1.20 |
| Antidiabetic drugs | ||||
| No | 1 | 1 | ||
| Yes | 1.02 | 0.95 to 1.10 | 1.05 | 0.97 to 1.14 |
| ‡Chronic disease score | ||||
| 0–1 | 1 | 1 | ||
| 2–4 | 0.92 | 0.86 to 0.99 | 0.99 | 0.91 to 1.07 |
| >4 | 0.89 | 0.83 to 0.96 | 0.96 | 0.88 to 1.05 |
| Hospitalisation for ischaemic heart disease in 2 years before index date | ||||
| No | 1 | 1 | ||
| Yes | 0.76 | 0.68 to 0.85 | 0.78† | 0.70 to 0.88 |
